Skip to main content
Clinical Trials/NCT03210623
NCT03210623
Completed
Not Applicable

The Efficacy and Safety Study of Stent Retriever's(TonbridgeMT) Endovascular Therapy for Acute Ischemic Stroke

Zhuhai Tonbridge Medical Tech. Co., Ltd.17 sites in 1 country220 target enrollmentAugust 3, 2017
ConditionsIschemic Stroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ischemic Stroke
Sponsor
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Enrollment
220
Locations
17
Primary Endpoint
successful recanalization rate in patients
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The study is a prospective, multi-center, stratified randomized, single-blind, parallel assignment, active control, non-inferiority trial. Patients are randomized 1 : 1 to either stent retriever(TonbridgeMT) or Solitaire™ for endovascular therapy for AIS. The study aims to evaluate the benefit and safety of stent retriever(TonbridgeMT) for AIS therapy, as compared to Solitaire™.

Detailed Description

The main objective is to determine whether stent retriever(TonbridgeMT) will have non-inferior successful recanalization rate compared to Solitaire™ when applied to endovascular therapy for AIS. The secondary objectives is to verify whether there isn't significant differences in time to achieve recanalization, NIHSS score, mRS score, and transportation performance between stent retriever(TonbridgeMT) and Solitaire™ when applied to endovascular therapy for AIS. The third objectives is to verify whether there isn't significant differences in the rate of symptomatic intracranial hemorrhage, subarachnoid hemorrhage, adverse event(AE), serious adverse event(SAE), actual condition of AE and device deficiencies between stent retriever(TonbridgeMT) and Solitaire™ when applied to endovascular therapy for AIS.

Registry
clinicaltrials.gov
Start Date
August 3, 2017
End Date
August 27, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18≤ages≤80;
  • Baseline NIHSS score obtained prior to randomization must be lower than 30 points;
  • Acute occlusion(TICI 0-1) of the intracranial segment of internal carotid artery(ICA), or M1/M2 middle cerebral artery(MCA), or A1/A2 anterior cerebral artery(ACA), as evidenced by digital subtraction angiography(DSA);
  • Patient treatable within 6 hours of symptom onset(symptoms onset is defined as point in time the patient was last seen well (at baseline)) can accept the complete femoral artery puncture;
  • Pre-AIS mRS score lower than 2.

Exclusion Criteria

  • Computed tomography (CT) or magnetic resonance imaging (MRI) evidence of intracranial hemorrhage or massive cerebral infarction (ASPECTS score of\<6 or infarct volume≥70ml or volume\>1/3 blood supplying areas of MCA on CT/diffusion weighted imaging(DWI);
  • DSA evidence of simultaneous acute bilateral carotid occlusion;
  • DSA evidence of occlusions in the initial segment of carotid artery or carotid artery dissection or arteritis;
  • DSA evidence of tortuosity of cervical vessels precluding device delivery/deployment;
  • Hypertension (Systolic blood pressure(SBP)\>185 mm Hg or diastolic blood pressure(DBP)\>110 mm Hg) after using drug;
  • Platelet count\<40,000/μL and use of Novel Anticoagulant with International Normalized Ratio(INR)\>3.0;
  • Random blood glucose of\<2.7mmol/L or\>22.2mmol/L;
  • Patients with heart or lung or liver or renal failure or other sever disease(intracranial tumors, cerebral arteriovenous malformation (AVM), systemic infection, active disseminated intravascular coagulation, myocardial infarction within the past 12 months before enrollment, history of sever psychosis);
  • Patients who will not cooperate or tolerate interventional operation;
  • Anticipated life expectancy of less than 90 days;

Outcomes

Primary Outcomes

successful recanalization rate in patients

Time Frame: intraoperative immediate

Successful recanalization is defined as modified Thrombolysis In Cerebral Ischemia scale 2b or 3. And it is evaluated by DSA intraoperative immediately in both treatment groups

Secondary Outcomes

  • successful recanalization rate in vessels(intraoperative immediate)
  • Time to achieve recanalization(intraoperative immediate)
  • NIHSS score(baseline, 24±6d and 7±2d after operation)
  • mRS score(baseline, 90±14d after operation)
  • the ratio of mRS 0-2(baseline, 90±14d after operation)
  • transportation performance(intraoperative immediate)

Study Sites (17)

Loading locations...

Similar Trials